Migraine Clinical Trials

42 studies are recruiting for migraine in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

   This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   Central Research Associates, LLC (CRA) dba Flourish Research, Birmingham, Alabama

   Locations

   113 in total

   Run by

   TriGemX Bio, Inc.

   See if you can join NCT07645924 on ClinicalTrials.gov

2. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

   This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   Velocity Clinical Research, Phoenix, Phoenix, Arizona

   Locations

   72 in total

   Run by

   TriGemX Bio, Inc.

   See if you can join NCT07816367 on ClinicalTrials.gov

3. Dietary Intervention for Migraine Relief

   The goal of this clinical trial is to evaluate whether a low-glutamate diet can improve migraine symptoms in adults with migraine and to explore possible biological changes associated with dietary improvement. The study focuses on whether reducing dietary glutamate intake may influence processes in…

   Stage

   Not phased

   Ages

   18 to 75

   Site

   American University, Washington D.C., District of Columbia

   Run by

   American University

   See if you can join NCT07360405 on ClinicalTrials.gov

4. Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

   The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

   Stage

   Not phased

   Ages

   0 and older

   Site

   Evidera, a PPD business unit, Wilmington, North Carolina

   Run by

   Pfizer

   See if you can join NCT05046613 on ClinicalTrials.gov

5. A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

   Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocat…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tampa General Hospital Emergency Room, Tampa, Florida

   Run by

   University of South Florida

   See if you can join NCT07667621 on ClinicalTrials.gov

6. Overlapping Pain Trajectory Study

   The goal of this observational study is to learn about spatial and temporal nociceptive filtering in adolescents with chronic overlapping pain conditions (COPCs). The main questions it aims to answer are: 1. If spatial and temporal filtering of nociceptive information is disrupted in youth with COP…

   Stage

   Not phased

   Ages

   10 to 19

   Site

   Cincinnati Children's Hospital, Cincinnati, Ohio

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT05752396 on ClinicalTrials.gov

7. Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

   This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerab…

   Stage

   Phase 4

   Ages

   18 to 70

   Site

   Northern Arizona Healthcare, Flagstaff, Arizona

   Locations

   37 in total

   Run by

   Mayo Clinic

   See if you can join NCT06972056 on ClinicalTrials.gov

8. Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

   The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Advanced Investigative Medicine, Inc., Hawthorne, California

   Locations

   93 in total

   Run by

   Pfizer

   See if you can join NCT05156398 on ClinicalTrials.gov

9. A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

   The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Yale School of Medicine - The Scirex Clinical Research Unit, New Haven, Connecticut

   Locations

   64 in total

   Run by

   H. Lundbeck A/S

   See if you can join NCT05164172 on ClinicalTrials.gov

10. Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

    This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it. Adults with migraine will receive both the study medication (ASY202) and a placebo (inactive treatment) at different times during the study. Neither partic…

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Arizona Research Center, Phoenix, Arizona

    Locations

    20 in total

    Run by

    Aspeya, Inc.

    See if you can join NCT07646613 on ClinicalTrials.gov

11. RELAXaHEAD for Headache Patients (Phase III)

    This study is a fully powered, remote randomized control trial to evaluate RELAXaHEAD in people with migraine.

    Stage

    Not phased

    Ages

    16 to 80

    Site

    NYU Langone Health, New York, New York

    Run by

    NYU Langone Health

    See if you can join NCT06077838 on ClinicalTrials.gov

12. NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder

    Background: Mood disorders, such as bipolar disorder, can have serious effects on a person s life. People with bipolar disorder are more likely to have heart disease and abuse substances. In this natural history study, researchers would like to learn more about the connection between exercise and m…

    Stage

    Not phased

    Ages

    8 to 70

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Mental Health (NIMH)

    See if you can join NCT05669703 on ClinicalTrials.gov

13. Study of EVO756 in Adults With Migraine

    This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.

    Stage

    Phase 2

    Ages

    18 to 64

    Site

    Trialsphere Corp, Chandler, Arizona

    Locations

    35 in total

    Run by

    Evommune, Inc.

    See if you can join NCT07616128 on ClinicalTrials.gov

14. The Effect of Remote Electrical Neuromodulation (REN) on Conditioned Pain Modulation (CPM) in Migraine and Fibromyalgia

    Migraine and Fibromyalgia (FM) are chronic pain disorders characterized by altered central pain processing and impaired endogenous pain inhibition. FM presents with widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive symptoms and is strongly associated with central sensitizat…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Rambam Health Care Campus, Haifa,

    Locations

    2 in total

    Run by

    Theranica

    See if you can join NCT07841509 on ClinicalTrials.gov

15. A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache

    Rimegepant (Nurtec) is an orally administered small molecule CGRP receptor antagonist with efficacy in the acute treatment of migraine. Rizatriptan benzoate (MAXALT), is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Rizatriptan binds with high affinity to human cloned 5-HT1B an…

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Maimonides Medical Center, Brooklyn, New York

    Run by

    Antonios Likourezos

    See if you can join NCT06473597 on ClinicalTrials.gov

16. EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine

    EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine who have undergone or plan to undergo middle meningeal artery (MMA) e…

    Stage

    Not phased

    Ages

    18 to 64

    Site

    Cortex Neurovascular / TRA Union, Tacoma, Washington

    Run by

    Cortex Neurovascular

    See if you can join NCT07652034 on ClinicalTrials.gov

17. Responding With Evidence and Access for Childhood Headaches

    This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for yo…

    Stage

    Not phased

    Ages

    10 to 17

    Site

    University of Alabama at Birmingham Children's of Alabama, Birmingham, Alabama

    Locations

    15 in total

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT05889624 on ClinicalTrials.gov

18. Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

    Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related p…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    Mayo Clinic in Arizona, Phoenix, Arizona

    Run by

    Mayo Clinic

    See if you can join NCT06401642 on ClinicalTrials.gov

19. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how s…

    Stage

    Phase 3

    Ages

    6 to 17

    Site

    Rehabilitation & Neurological Services /ID# 229969, Huntsville, Alabama

    Locations

    129 in total

    Run by

    AbbVie

    See if you can join NCT05125302 on ClinicalTrials.gov

20. Objectively Diagnose and Monitor Treatment of Light Sensitivity

    The purpose of this project is to provide a new framework for diagnosing and monitoring treatment of light sensitivity and headache by objective measurement of facial features, pupil responses, retinal electrical responses and autonomic nerve responses to light.

    Stage

    Not phased

    Ages

    18 to 80

    Site

    University of Iowa Health Care, Iowa City, Iowa

    Run by

    Randy Kardon

    See if you can join NCT03694626 on ClinicalTrials.gov

21. Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine

    This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used …

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Johns Hopkins Medicine, Baltimore, Maryland

    Run by

    Johns Hopkins University

    See if you can join NCT07223008 on ClinicalTrials.gov

22. Emgality for Migraine in Breastmilk

    The goal of this project is to evaluate galcanezumab transfer into maternal breastmilk, and to evaluate infant (growth, development, constipation, colic, infections) and maternal (headache) outcomes for dyads in which the mother was treated with galcanezumab and to compare outcomes for infants who …

    Stage

    Not phased

    Ages

    18 to 45

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT06085144 on ClinicalTrials.gov

23. Headache Ear Auditory Dizziness Sinus (HEADS) Registry

    The Headache, Ear, Auditory, Dizziness, Sinus (HEADS) Registry is a study over time of individuals living in the United States who experience sinus, vestibular, auditory, and headache symptoms. Through an online portal, participants are asked questions about their symptoms, how they have affected t…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Association of Migraine Disorders, North Kingstown, Rhode Island

    Run by

    Association of Migraine Disorders

    See if you can join NCT07754266 on ClinicalTrials.gov

24. Migraine in Adolescents

    Aim 1. To identify psychophysical and neural factors predicting migraine onset in adolescents Aim 2a. To determine hormonal, psychophysical, and neural changes associated with migraine onset. Aim 2b. To identify the temporal relationships between hormonal, psychophysical, and neural changes precedi…

    Stage

    Not phased

    Ages

    10 to 13

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT05654012 on ClinicalTrials.gov

25. Mechanistic Studies of Psilocybin in Headache Disorders

    In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect. This study will measure brain resting state functional connectivity (fMRI), cent…

    Stage

    EARLY_Phase 1

    Ages

    21 to 70

    Site

    VA Connecticut Healthcare System, West Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT06464367 on ClinicalTrials.gov